Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HCN1 | O60741 | 1/20 | 0.39 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506099 | 0.87 | RPS6KB1 (0.40) | NPC1RAB9AKMT2AATMOPRM1 | |
| SCHEMBL6387711 | 0.71 | DAPK3 (0.40) | RPS6KB1 | |
| SCHEMBL6389539 | 0.71 | DAPK3 (0.40) | RPS6KB1 | |
| SCHEMBL6386637 | 0.69 | POLB (0.51) | NPC1RAB9AHPGD | |
| SCHEMBL6501631 | 0.69 | POLB (0.51) | NPC1RAB9AHPGD | |
| SCHEMBL6386456 | 0.69 | TSHR (0.44) | NPC1RAB9AKMT2ARPS6KB1 | |
| SCHEMBL6499328 | 0.69 | ALDH1A1 (0.50) | MEN1KMT2A | |
| SCHEMBL6508183 | 0.69 | ALDH1A1 (0.50) | MEN1KMT2A | |
| SCHEMBL30855410 | 0.68 | HPGD (0.59) | NPC1RAB9AMEN1KMT2AOPRM1 | |
| SCHEMBL30848453 | 0.68 | HPGD (0.60) | NPC1RAB9AMEN1KMT2AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | NPC1 277/4885RAB9A 2649/4885MEN1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.